Atara Biotherapeutics (ATRA) Other Non-Current Assets (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Other Non-Current Assets came in at $890000.0 in Q1 2026, down 68.71% YoY from $2.8 million in Q1 2025, and little changed on a QoQ basis from $886000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Other Non-Current Assets data on file, last reported at $890000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 68.71% year-over-year to $890000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $890000.0 (down 68.71% YoY) and the FY2025 annual result came in at $886000.0, down 71.45% from the prior year.
- Other Non-Current Assets was little changed at $890000.0 in Q1 2026, from $886000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $7.0 million in Q4 2022 to a low of $881000.0 in Q3 2025.
- A 5-year average of $3.4 million and a median of $3.2 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 484.83% — and 2025, when it slumped 74.31%.
- Tracing ATRA's Other Non-Current Assets over 5 years: stood at $7.0 million in 2022, then plunged by 30.98% to $4.8 million in 2023, then slumped by 35.94% to $3.1 million in 2024, then sank by 71.45% to $886000.0 in 2025, then gained by 0.45% to $890000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $890000.0 (Q1 2026), $886000.0 (Q4 2025), and $881000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | 765,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 765,000.00 |
| Mar 31, 2026 | 890,000.00 |
| Dec 31, 2025 | 886,000.00 |
| Sep 30, 2025 | 881,000.00 |
| Jun 30, 2025 | 927,000.00 |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 3.10 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 4.84 Mn |
| Sep 30, 2023 | 6.29 Mn |
| Jun 30, 2023 | 6.58 Mn |
| Mar 31, 2023 | 6.91 Mn |
| Dec 31, 2022 | 7.02 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 1.30 Mn |
| Dec 31, 2021 | 1.20 Mn |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 1.20 Mn |